ATHN - athenahealth, Inc.
| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (3Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
- Zacks•3 months ago
Healthcare's Near-Term Prospects Bright: 3 ETFs in Focus
The healthcare space might have seen a sluggish year so far. But its valuation and near-term prospects make it a good space for investments right now.
- Insider Monkey•4 months ago
Paul Glazer’s Glazer Capital’s Return, AUM, and Holdings
Twenty years ago, Paul J. Glazer launched his own merger arbitrage hedge fund, which he called Glazer Capital. The fund, which has $1.3 billion in AUM (as of June 6th, 2017) is headquartered in New York City, and it was registered with the US Securities and Exchange Commission as an Investment Adviser in 2006. Paul […]
- Markit•5 months ago
See what the IHS Markit Score report has to say about athenahealth Inc.
athenahealth Inc NASDAQ/NGS:ATHNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ATHN with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 1. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ATHN totaled $1.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•6 months ago
Athenahealth (ATHN) Earnings Expected to Grow: Should You Buy?
Athenahealth (ATHN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•6 months ago
Here's Why Investors Should Retain athenahealth (ATHN) Stock
athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.
- Zacks•6 months ago
Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up
Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.
- Zacks•6 months ago
Integra LifeSciences Unveils Titan RSS-S, Widens Portfolio
The latest launch reflects Integra LifeSciences' (IART) consistent efforts to boost the Orthopedics and Tissue Technologies segment.
- GlobeNewswire•6 months ago
Report: Exploring Fundamental Drivers Behind Akamai Technologies, Dynex Capital, MedEquities Realty Trust, HFF, Penumbra, and athenahealth — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•6 months ago
Integra (IART) Rises 5% on Robust Preliminary Q4 Results
Integra's (IART) total Q4 revenues are likely to be at the upper end of its prior guided range.
- Zacks•6 months ago
Boston Scientific Gains on Impressive Preliminary Q4 Results
Boston Scientific's (BSX) solid top line is expected to be backed by growth across all segments and geographical regions in Q4.
- Zacks•6 months ago
ResMed Announces Complete Mobi Launch in US Markets for COPD
ResMed (RMD) progresses with efforts to boost Respiratory Care suite.
- Zacks•6 months ago
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
- Zacks•6 months ago
Hologic Stock Rides on Impressive Preliminary Q1 Result
Hologic's (HOLX) strong top line is primarily expected on the back of balanced growth across a majority of the company's segments in Q1.
- Zacks•6 months ago
ResMed Closes Propeller Health Buyout, Boosts COPD Suite
ResMed (RMD) expects to boost the Respiratory Care suite with the recently-completed Propeller Health buyout.
- GlobeNewswire•6 months ago
MERGER ALERT – IMPV and ATHN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
NEW YORK, Jan. 07, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
- Zacks•6 months ago
Cardiovascular Systems Expands Portfolio Amid Stiff Rivalry
Cardiovascular Systems (CSII) continues to expand its portfolio to widen the company's reach. However, Cardiovascular Systems operating in a highly competitive environment is a concern.
- Zacks•6 months ago
Neogen's Canadian Lab Buyout to Boost Genomics Business
Neogen (NEOG) continues to adopt initiatives to boost the genomics business.
- Zacks•6 months ago
LabCorp Rides on Covance Business Amid Reimbursement Woes
Within Covance Drug Development business, LabCorp (LH) aims at reaping huge profits via expanded solutions and better operational skills.
- Zacks•6 months ago
AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife
AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.
- Zacks•6 months ago
Cerner (CERN) Collaborates With McKesson's CoverMyMeds
Cerner's (CERN) ePrescribe workflow solution is likely to partner with CoverMyMeds' RxBenefit Clarity solution for prescription price transparency.
